Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogeneic cell immunotherapies

The collaborators have been awarded £800,000 of Innovate UK Biomedical Catalyst funding to develop an integrated and scalable platform to manufacture allogeneic induced pluripotent stem cell (iPSC) derived immunotherapies.

The project consortium is led by Plasticell, a biotechnology company developing next-generation stem cell technologies and advanced therapies. The team additionally comprises the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, and Imperial College London.

Cellular immunotherapies, which direct the immune system to attack cancerous cells, have revolutionised treatment for hard-to-treat blood cancers. The currently available therapies use cells collected from patients which are modified in the laboratory so they better recognise and attack cancer cells. As these treatments, known as autologous therapies, use cells taken from individual patients they are of variable quality and require a complex and costly manufacturing process.

In contrast, allogeneic therapies can be made from a master cell bank of pre-qualified, expanded and modified cells, rather than cells taken from individual patients. Unlike autologous therapies, allogeneic therapies could be manufactured centrally at commercial scale. This means that they have potential to be produced more cost effectively and so could result in broader access to life-saving therapies for cancer patients.

Over the course of the two year project, the collaborators will combine two innovative technology platforms, developed by Plasticell and CGT Catapult, to allow for the manufacture of iPSC-derived natural killer (NK) cells. CGT Catapult will develop scaled-up processes and analytics which could allow for the protocols to be used in good manufacturing practice (GMP) settings. This bioreactor-based process will help enable the development of a manufacturing platform for allogeneic iPSC-derived natural killer (NK) cell immunotherapies that could produce these therapies on an industrial scale.

Published on the 8th of August 2023. Read the entire news report here.

 


OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2024). Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogeneic cell immunotherapies. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/11osg


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.